Book a Meeting

Non-Fucosylated Anti-Human AbGn-7 (AbGn-7) Therapeutic Antibody (CAT#: BioBet-1615ZP) Datasheet

Target
AbGn-7
Isotype
Chimeric IgG
Description
ADCC-Enhanced anti-AbGn-7 (AbGn-7) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Gastric Cancer; Pancreatic Cancer; Solid Tumors
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced AbGn-7 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
AbGn-7
Full Name
AbGn-7 antigen
Background
AbGn-7 antigen like a Lewis-A-like carbohydrate antigen is expressed in colorectal cancer tissue.
Alternative Names
AbGn-7; AbGn-7 antigen
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Chimeric IgG
Antibody Clone
AbGn-7
Host
Chimeric
Species Reactivity
Human
Description
A chimeric monoclonal antibody, AbGn-7, which targets AbGn-7 antigen, is used for the potential clinical use to treat colorectal cancer.
Indication
Gastric Cancer; Pancreatic Cancer; Solid Tumors

Gastric Cancer; Pancreatic Cancer; Solid Tumors

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany